Related Experiment Video
Updated: Feb 6, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Gonzalo Recondo1, Francesco Facchinetti2, Ken A Olaussen1
1INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France.
For advanced non-small cell lung cancer (NSCLC) with ALK or EGFR mutations, next-generation tyrosine kinase inhibitors (TKIs) show promise as a first-line treatment over traditional sequential therapy. This review examines evidence for both approaches in EGFR-driven or ALK-driven NSCLC.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- The standard treatment for advanced non-small cell lung cancer (NSCLC) with ALK rearrangements or EGFR mutations involves sequential tyrosine kinase inhibitors (TKIs).
- This traditional approach administers first-generation TKIs, followed by next-generation TKIs or chemotherapy upon disease progression.
Purpose of the Study:
- To review and compare the evidence for sequential TKI therapy versus frontline next-generation TKIs in advanced NSCLC.
- To discuss the suitability of these strategies for patients with EGFR-driven or ALK-driven NSCLC.
Main Methods:
- Review of preclinical and clinical evidence.
- Analysis of treatment strategies for ALK-rearranged and EGFR-mutated NSCLC.
Main Results:
- Next-generation TKIs used as first-line therapy demonstrate improved progression-free survival and intracranial disease control.
- First-line next-generation TKIs generally exhibit a favorable toxicity profile compared to sequential approaches.
Conclusions:
- Frontline use of next-generation TKIs presents a viable alternative to traditional sequential treatment for advanced NSCLC.
- The choice of strategy should be tailored to individual patient profiles in EGFR-driven or ALK-driven NSCLC.
Related Concept Videos
ATP Driven Pumps I: An Overview
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
Xylem and Transpiration-driven Transport of Resources
ATP Driven Pumps II: P-type Pumps
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...
ATP Driven Pumps III: V-type Pumps
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
DC Generator
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....

